Birth of Mitochondrial Mutant Pigs: Opening a New Door to Human Premature Aging Mechanisms and Preclinical Research
Background
Mitochondria are often referred to as the powerhouses of the cell, utilizing their own mitochondrial DNA (mtDNA) in the process of energy production. As organisms age, mutations in mtDNA accumulate, leading to impaired cellular function, which is directly linked to degenerative diseases. Previous research has focused on modifying the DNA polymerase gamma (POLG) gene, which lacks proofreading functions that correct replication errors during the cloning process. Transgenic mouse models have been widely used to elucidate aging mechanisms. However, rodent models differ significantly from humans in metabolic rates, lifespan, and other physiological characteristics, making it difficult to accurately reflect human aging patterns. The vast differences in metabolic rates and organ development speeds create a substantial biological gap between laboratory mice and human patients. This has consistently highlighted the need for large animal disease models that are similar to humans in organ size, lifespan, and metabolic flow.
Key Findings
The research team combined precision gene-editing technology, Prime Editing (PE), with somatic cell nuclear transfer (SCNT) technology to conduct the study. As a result, they successfully generated pigs expressing proofreading-deficient POLG, which induces replication errors in mtDNA. Using precise prime editing, they introduced genetic defects while preventing unwanted mutations outside the target site, and then used somatic cell cloning technology to grow and implant the embryos. The resulting model pigs exhibited a significantly higher accumulation rate of mtDNA mutations in somatic cells compared to the control group. This genomic damage led to rapid physical aging. The model pigs experienced multiple premature aging symptoms, including rapid weight loss, poor coat quality, and anemia. Histologically, the pigs showed structural destruction of the skin and testicular interstitium, along with increased cell apoptosis. Additionally, the activity levels of aging markers were elevated, ultimately resulting in a shortened lifespan compared to normal pigs.
Significance and Outlook
This study is of great significance as it bridges the physiological gap of rodent models and demonstrates aging mechanisms in large animals with metabolic profiles similar to humans. It confirms that mitochondrial dysfunction observed in aging mice is similarly reproduced in large animals more comparable to human physiology. This opens the door to more reliable in vivo validation of candidate drugs for controlling mitochondrial diseases and systemic aging. However, the high costs associated with long-term breeding and the prolonged reproductive cycle remain challenges for large animal model research. It is still difficult to establish large cohorts for high-throughput screening due to physical and logistical barriers. The research team plans to conduct long-term tracking of these gene-edited pigs to further clarify the links between aging-related chronic diseases such as neurodegenerative disorders and immune decline.
The accumulation of mitochondrial DNA (mtDNA) mutations is a primary driver of mitochondrial dysfunction, which is intrinsically linked to aging and various pathologies. POLG, the catalytic subunit of DNA polymerase gamma, is essential for mtDNA replication; notably, a deficiency in its proofreading function precipitates the accumulation of mtDNA mutations. In this study, by combining prime editing with somatic cell nuclear transfer technology, we successfully generated a mitochondrial mutator pig model expressing proofreading-deficient POLG. These pigs exhibited elevated somatic mtDNA mutation loads and recapitulated key premature aging phenotypes, including weight loss, rough hair coat, anemia, structural alterations in the skin and testicular interstitium, increased apoptosis, and the up-regulation of senescence-associated markers, culminating in shortened life span. Given the physiological and metabolic similarities between pigs and humans, this mitochondrial mutator pig model represents an ideal preclinical tool for dissecting the mechanistic role of mtDNA mutations in aging and age-related pathologies and for accelerating the translation of therapeutic strategies.
The newly established mitochondrial mutant pig model has the potential to significantly enhance the efficiency of drug candidate evaluation across the pharmaceutical and biotechnology industries. This is because scenarios in which the mechanisms of drug action and pharmacokinetic properties are reviewed under physiological conditions similar to those in humans can now become a reality. Specifically, the model allows for real-time, precise measurement of cell apoptosis inhibition rates and the degree of anemia improvement at both tissue and organismal levels when low-molecular-weight compounds or gene therapies are administered to restore mitochondrial activity. Furthermore, the model can be extended to serve as a platform for evaluating the efficacy of anti-aging compounds and beauty products by directly monitoring structural changes in the skin during the aging process. High-precision preclinical screening using large animals is expected to serve as a practical key to increasing clinical trial success rates and reducing development timelines.